IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva

Blockhead05:10

Catalyst Pharmaceuticals (CPRX) struck a deal Wednesday with Teva Pharmaceutical (TEVA) that will prevent the generic-drug maker from knocking off Firdapse until 2035. ↑ X How To Buy Stocks: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502082277?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2023/01/Stock-catalystpharma-firdapse-01-company-150x150.jpg","is_english":true,"pubTime":"2025-01-09 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502082277","market":"sg","top_or_hot":-1,"title":"IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva","media":"Blockhead","content":"<div>\n<p>Catalyst Pharmaceuticals (CPRX) struck a deal Wednesday with Teva Pharmaceutical (TEVA) that will prevent the generic-drug maker from knocking off Firdapse until 2035.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: ...</p>\n\n<a href=\"https://www.investors.com/news/technology/catalyst-pharmaceuticals-catalyst-stock-teva-pharmaceutical-firdapse-generic/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 05:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/catalyst-pharmaceuticals-catalyst-stock-teva-pharmaceutical-firdapse-generic/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalyst Pharmaceuticals (CPRX) struck a deal Wednesday with Teva Pharmaceutical (TEVA) that will prevent the generic-drug maker from knocking off Firdapse until 2035.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: ...</p>\n\n<a href=\"https://www.investors.com/news/technology/catalyst-pharmaceuticals-catalyst-stock-teva-pharmaceutical-firdapse-generic/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://www.investors.com/news/technology/catalyst-pharmaceuticals-catalyst-stock-teva-pharmaceutical-firdapse-generic/","article_id":"2502082277","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2023/01/Stock-catalystpharma-firdapse-01-company-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502082277","pubTimestamp":1736370604,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","BK4007":"制药","BK4557":"大麻股","IBD":"Inspire Corporate Bond ETF","BK4584":"避孕概念","CPRX":"Catalyst Pharmaceutical Partners","TEVA":"梯瓦制药","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4596":"哈里斯概念"},"translate_title":"IBD技术领导者Catalyst在与梯瓦(Teva)达成重要协议后股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1,"IBD":1,"TEVA":1},"content_text":"Catalyst Pharmaceuticals (CPRX) struck a deal Wednesday with Teva Pharmaceutical (TEVA) that will prevent the generic-drug maker from knocking off Firdapse until 2035.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\n\n\nFirdapse treats Lambert-Eaton myasthenic syndrome, or LEMS. LEMS is a rare autoimmune disorder that weakens the muscles and makes it difficult to move. It's often associated with small cell lung cancer. Firdapse is one of three drugs Catalyst sells.\nUnder the settlement, Teva won't market the proposed generic if it receives Food and Drug Administration approval until at least Feb. 25, 2035. The companies will also end all ongoing patent litigation over Firdapse.\nIn response, shares of Catalyst Pharmaceuticals rocketed 16.7%, closing at 22.80. That helped shares rise above their 50-day moving average, MarketSurge shows. But, in after-hours trades, Catalyst stock was down about 4.3%. Teva stock closed down a fraction.\nCatalyst stock lands on the IBD Tech Leaders list.\nFollow Allison Gatlin on X/Twitter at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nInari Medical Catapults — Again — After Stryker Confirms $4.9 Billion Deal\nModerna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike\nStocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks\nGet Timely Buy & Sell Alerts With IBD Leaderboard\nBest Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502082277"}